Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen

G. Bolis, G. Scarfone, L. Luchini, C. Ferraris, F. Zanaboni, M. Presti, G. Giardina, A. Villa, F. Parazzini

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Response to a second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with cisplatin- or carboplatin-based regimens was analysed in a clinical series observed between 1984 and 1991. Women who achieved pathological complete response or pathological optimal partial remission after first-line cisplatin- or carboplatin-based regimens were treated at recurrence or progression, occurring at least 4 months after first-line treatment, with second-line chemotherapy. A total of 72 women were included in the analysis. Second-line chemotherapy regimens were: cisplatin 1 mg/kg weekly for seven courses plus epirubicin 70 mg/m2 intravenously (i.v.) every 3 weeks for three courses (28 subjects), cisplatin 1 mg/kg plus etoposide 90 mg/m2 i.v. weekly for a total of seven courses (11 subjects) and cisplatin Img/kg weekly for nine courses plus carboplatin 250 mg/m, every 3 weeks for three courses (33 subjects). Of the 72 women, 22 (31%, 14 clinical, 8 pathological) had a complete response and 28 (39%), a partial response (24 clinical, 4 pathological). The 24-month cumulative survival probability was 63% in women with complete response, 32% in those who had partial response, but all the 22 nonresponders died within 24 months from diagnosis of recurrence (log rank test P <0.05). The frequency of complete response and partial response increased with the interval between first diagnosis and recurrence: among the 33 women who had recurrent disease to <18 months from first diagnosis, complete response or partial response was obtained in 20 (61%) subjects, this figure was 67% (14 out of 21 women) among subjects who had recurrent disease between 18 and <36 months from first diagnosis and 89% (16/18) among those who had recurrence ? 36 months. In comparison with women who had recurrence 4-<18 months from first diagnosis, the OR of response was 1.3 (95% CI 0.4-4.1) for those who had recurrence between 18 and <36 and 5.2 (95% CI 1.1-24.3) for those who had recurrence ? 36 months from surgery (X2 1 trend p <0.05). Survival rate after the end of second line chemotherapy for women who relapsed 4-<18 months, 18-<36 or 36 months or more after surgery were, respectively, 24, 20 and 67% (log rank test, P <0.05). Age at first diagnosis, histology, stage, and grading of the disease at first diagnosis and site of recurrence were not associated with response to second-line therapy.

Original languageEnglish
Pages (from-to)1764-1768
Number of pages5
JournalEuropean Journal of Cancer
Volume30
Issue number12
DOIs
Publication statusPublished - 1994

Fingerprint

Carboplatin
Ovarian Neoplasms
Cisplatin
Recurrence
Drug Therapy
Epirubicin
Etoposide
Histology
Survival Rate
Survival
Therapeutics

Keywords

  • chemotherapy
  • ovarian cancer
  • prognostic factors
  • second-line treatment

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen. / Bolis, G.; Scarfone, G.; Luchini, L.; Ferraris, C.; Zanaboni, F.; Presti, M.; Giardina, G.; Villa, A.; Parazzini, F.

In: European Journal of Cancer, Vol. 30, No. 12, 1994, p. 1764-1768.

Research output: Contribution to journalArticle

@article{eaf0b69fa3f148d0865435f7248a253e,
title = "Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen",
abstract = "Response to a second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with cisplatin- or carboplatin-based regimens was analysed in a clinical series observed between 1984 and 1991. Women who achieved pathological complete response or pathological optimal partial remission after first-line cisplatin- or carboplatin-based regimens were treated at recurrence or progression, occurring at least 4 months after first-line treatment, with second-line chemotherapy. A total of 72 women were included in the analysis. Second-line chemotherapy regimens were: cisplatin 1 mg/kg weekly for seven courses plus epirubicin 70 mg/m2 intravenously (i.v.) every 3 weeks for three courses (28 subjects), cisplatin 1 mg/kg plus etoposide 90 mg/m2 i.v. weekly for a total of seven courses (11 subjects) and cisplatin Img/kg weekly for nine courses plus carboplatin 250 mg/m, every 3 weeks for three courses (33 subjects). Of the 72 women, 22 (31{\%}, 14 clinical, 8 pathological) had a complete response and 28 (39{\%}), a partial response (24 clinical, 4 pathological). The 24-month cumulative survival probability was 63{\%} in women with complete response, 32{\%} in those who had partial response, but all the 22 nonresponders died within 24 months from diagnosis of recurrence (log rank test P <0.05). The frequency of complete response and partial response increased with the interval between first diagnosis and recurrence: among the 33 women who had recurrent disease to <18 months from first diagnosis, complete response or partial response was obtained in 20 (61{\%}) subjects, this figure was 67{\%} (14 out of 21 women) among subjects who had recurrent disease between 18 and <36 months from first diagnosis and 89{\%} (16/18) among those who had recurrence ? 36 months. In comparison with women who had recurrence 4-<18 months from first diagnosis, the OR of response was 1.3 (95{\%} CI 0.4-4.1) for those who had recurrence between 18 and <36 and 5.2 (95{\%} CI 1.1-24.3) for those who had recurrence ? 36 months from surgery (X2 1 trend p <0.05). Survival rate after the end of second line chemotherapy for women who relapsed 4-<18 months, 18-<36 or 36 months or more after surgery were, respectively, 24, 20 and 67{\%} (log rank test, P <0.05). Age at first diagnosis, histology, stage, and grading of the disease at first diagnosis and site of recurrence were not associated with response to second-line therapy.",
keywords = "chemotherapy, ovarian cancer, prognostic factors, second-line treatment",
author = "G. Bolis and G. Scarfone and L. Luchini and C. Ferraris and F. Zanaboni and M. Presti and G. Giardina and A. Villa and F. Parazzini",
year = "1994",
doi = "10.1016/0959-8049(94)E0125-N",
language = "English",
volume = "30",
pages = "1764--1768",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "12",

}

TY - JOUR

T1 - Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen

AU - Bolis, G.

AU - Scarfone, G.

AU - Luchini, L.

AU - Ferraris, C.

AU - Zanaboni, F.

AU - Presti, M.

AU - Giardina, G.

AU - Villa, A.

AU - Parazzini, F.

PY - 1994

Y1 - 1994

N2 - Response to a second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with cisplatin- or carboplatin-based regimens was analysed in a clinical series observed between 1984 and 1991. Women who achieved pathological complete response or pathological optimal partial remission after first-line cisplatin- or carboplatin-based regimens were treated at recurrence or progression, occurring at least 4 months after first-line treatment, with second-line chemotherapy. A total of 72 women were included in the analysis. Second-line chemotherapy regimens were: cisplatin 1 mg/kg weekly for seven courses plus epirubicin 70 mg/m2 intravenously (i.v.) every 3 weeks for three courses (28 subjects), cisplatin 1 mg/kg plus etoposide 90 mg/m2 i.v. weekly for a total of seven courses (11 subjects) and cisplatin Img/kg weekly for nine courses plus carboplatin 250 mg/m, every 3 weeks for three courses (33 subjects). Of the 72 women, 22 (31%, 14 clinical, 8 pathological) had a complete response and 28 (39%), a partial response (24 clinical, 4 pathological). The 24-month cumulative survival probability was 63% in women with complete response, 32% in those who had partial response, but all the 22 nonresponders died within 24 months from diagnosis of recurrence (log rank test P <0.05). The frequency of complete response and partial response increased with the interval between first diagnosis and recurrence: among the 33 women who had recurrent disease to <18 months from first diagnosis, complete response or partial response was obtained in 20 (61%) subjects, this figure was 67% (14 out of 21 women) among subjects who had recurrent disease between 18 and <36 months from first diagnosis and 89% (16/18) among those who had recurrence ? 36 months. In comparison with women who had recurrence 4-<18 months from first diagnosis, the OR of response was 1.3 (95% CI 0.4-4.1) for those who had recurrence between 18 and <36 and 5.2 (95% CI 1.1-24.3) for those who had recurrence ? 36 months from surgery (X2 1 trend p <0.05). Survival rate after the end of second line chemotherapy for women who relapsed 4-<18 months, 18-<36 or 36 months or more after surgery were, respectively, 24, 20 and 67% (log rank test, P <0.05). Age at first diagnosis, histology, stage, and grading of the disease at first diagnosis and site of recurrence were not associated with response to second-line therapy.

AB - Response to a second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with cisplatin- or carboplatin-based regimens was analysed in a clinical series observed between 1984 and 1991. Women who achieved pathological complete response or pathological optimal partial remission after first-line cisplatin- or carboplatin-based regimens were treated at recurrence or progression, occurring at least 4 months after first-line treatment, with second-line chemotherapy. A total of 72 women were included in the analysis. Second-line chemotherapy regimens were: cisplatin 1 mg/kg weekly for seven courses plus epirubicin 70 mg/m2 intravenously (i.v.) every 3 weeks for three courses (28 subjects), cisplatin 1 mg/kg plus etoposide 90 mg/m2 i.v. weekly for a total of seven courses (11 subjects) and cisplatin Img/kg weekly for nine courses plus carboplatin 250 mg/m, every 3 weeks for three courses (33 subjects). Of the 72 women, 22 (31%, 14 clinical, 8 pathological) had a complete response and 28 (39%), a partial response (24 clinical, 4 pathological). The 24-month cumulative survival probability was 63% in women with complete response, 32% in those who had partial response, but all the 22 nonresponders died within 24 months from diagnosis of recurrence (log rank test P <0.05). The frequency of complete response and partial response increased with the interval between first diagnosis and recurrence: among the 33 women who had recurrent disease to <18 months from first diagnosis, complete response or partial response was obtained in 20 (61%) subjects, this figure was 67% (14 out of 21 women) among subjects who had recurrent disease between 18 and <36 months from first diagnosis and 89% (16/18) among those who had recurrence ? 36 months. In comparison with women who had recurrence 4-<18 months from first diagnosis, the OR of response was 1.3 (95% CI 0.4-4.1) for those who had recurrence between 18 and <36 and 5.2 (95% CI 1.1-24.3) for those who had recurrence ? 36 months from surgery (X2 1 trend p <0.05). Survival rate after the end of second line chemotherapy for women who relapsed 4-<18 months, 18-<36 or 36 months or more after surgery were, respectively, 24, 20 and 67% (log rank test, P <0.05). Age at first diagnosis, histology, stage, and grading of the disease at first diagnosis and site of recurrence were not associated with response to second-line therapy.

KW - chemotherapy

KW - ovarian cancer

KW - prognostic factors

KW - second-line treatment

UR - http://www.scopus.com/inward/record.url?scp=0028113429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028113429&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(94)E0125-N

DO - 10.1016/0959-8049(94)E0125-N

M3 - Article

VL - 30

SP - 1764

EP - 1768

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 12

ER -